The radioligand therapeutics market in cancer treatment is estimated to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at a 13.1% CAGR. Growth is supported by approved products Pluvicto and Lutathera and expanding use of PSMA and SSTR-targeted therapies.
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
Cabozantinib plus metronomic temozolomide showed a 15% response rate and 28.5-month median progression-free survival in a phase 2 NET study. A separate analysis found cabozantinib cost-effective for pancreatic NETs, but not extrapancreatic NETs, in China and the U.S.
The global radioligand therapy market is projected to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at 13.1% CAGR, driven by FDA label expansions, earlier-line treatment positioning, and substantial private investment in isotope production infrastructure.
Researchers have developed modified CAR T cells that overcome prostaglandin E2 suppression in solid tumors and a selective therapy targeting IGHV4-34 that spares healthy immune cells, addressing key limitations in current treatments.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07534371 |
Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study |
ACTIVE_NOT_RECRUITING | |
| NCT07450287 |
CardioNETPOL National Registry of Carcinoid Heart Disease |
NOT_YET_RECRUITING | |
| NCT07404176 |
Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors |
RECRUITING | PHASE2 |
| NCT07369505 |
Sapu003 in Advanced mTOR-sensitive Solid Tumors |
RECRUITING | PHASE1 |
| NCT07366658 |
Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients |
NOT_YET_RECRUITING | PHASE1 |
| NCT07314164 |
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment |
RECRUITING | |
| NCT07272512 |
Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms |
RECRUITING | PHASE4 |
| NCT07165132 |
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. |
RECRUITING | PHASE1 |
| NCT07151391 |
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue) |
RECRUITING | PHASE2 |
| NCT07129252 |
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
